CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis, Inc. announced that Molina Healthcare will cover its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, which is FDA-cleared for treating functional abdominal pain ...
NeurAxis, a neuromodulation tech company, offers IB-Stim, the only FDA-cleared device for treating IBS-related pain in children, promising revenue growth and profitability. The IB-Stim device, worn ...
CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address ...
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that ...
CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback